Gujarat Kidney Super Speciality Ltd vs Krishna Institute Of Medical Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 31, 2026

Key Highlights

The Latest Trading Price of Gujarat Kidney & Super Speciality Ltd is ₹ 163.5 as of 30 Oct 15:30 . The P/E Ratio of Gujarat Kidney & Super Speciality Ltd changed from 51.4 on March 2026 to 51.4 on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Krishna Institute of Medical Sciences Ltd changed from 33.2 on March 2022 to 103.1 on March 2026 . This represents a CAGR of 25.44% over 5 years The Market Cap of Gujarat Kidney & Super Speciality Ltd changed from ₹ 798.29 crore on March 2026 to ₹ 798.29 crore on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Krishna Institute of Medical Sciences Ltd changed from ₹ 11043 crore on March 2022 to ₹ 24910 crore on March 2026 . This represents a CAGR of 17.67% over 5 years The revenue of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 34.98 crore as compare to the Mar '26 revenue of ₹ 31.29 crore. This represent the growth of 11.79% The revenue of Krishna Institute of Medical Sciences Ltd for the Jun '26 is ₹ 1196 crore as compare to the Mar '26 revenue of ₹ 1086 crore. This represent the growth of 10.12% The ebitda of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 9.07 crore as compare to the Mar '26 ebitda of ₹ 7.01 crore. This represent the growth of 29.39% The ebitda of Krishna Institute of Medical Sciences Ltd for the Jun '26 is ₹ 240.8 crore as compare to the Mar '26 ebitda of ₹ 207.9 crore. This represent the growth of 15.82% The net profit of Gujarat Kidney & Super Speciality Ltd changed from ₹ 2.96 crore to ₹ 5.32 crore over 9 quarters. This represents a CAGR of 29.77% The net profit of Krishna Institute of Medical Sciences Ltd changed from ₹ 95.2 crore to ₹ 37.4 crore over 9 quarters. This represents a CAGR of -33.98% The Dividend Payout of Gujarat Kidney & Super Speciality Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Krishna Institute of Medical Sciences Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Gujarat Kidney & Super Speciality Ltd

Gujarat Kidney And Super Speciality Limited was incorporated under the name and style of Vihaan Medicare Private Limited', a private limited company, dated December 20, 2019 issued by the Registrar of Companies, Central Registration Centre.
Subsequently, the Company name was changed to Gujarat Kidney and Super Speciality Private Limited' and a fresh certificate of incorporation dated September 13, 2023 was issued by the Registrar of Companies, Gujarat at Ahmedabad.
Further, Company' status was changed to a public limited company and the name of Company was changed to Gujarat Kidney and Super Speciality Limited' dated November 24, 2023 by the ROCs, Ahmedabad. The Company operate a chain of mid-sized multispecialty healthcare institution and is engaged in providing comprehensive medical services, including inpatient and outpatient care, surgical procedures, diagnostic services, and emergency care.

About Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Limited (KIMS) was erstwhile incorporated as Jagjit Singh and Sons Private Limited', a Private Limited Company on July 26, 1973 in Mumbai.
Subsequently, the name of the Company changed to Krishna Institute of Medical Sciences Private Limited' on January 2, 2004 and further upon its conversion to a Public Company, the name was changed to Krishna Institute of Medical Sciences Limited' on January 29, 2004. The Company is one of the largest corporate groups in India, with hospitals in Telangana, Andhra Pradesh & Maharashtra providing multi-disciplinary integrated services with a focus on tertiary and quaternary healthcare at affordable cost.
It is engaged in rendering medical and healthcare services.
It operate 12 multi-specialty hospitals under the 'KIMS Hospitals' brand, with an aggregate capacity of over 5000 beds.

FAQs for the comparison of Gujarat Kidney & Super Speciality Ltd and Krishna Institute of Medical Sciences Ltd

Which company has a larger market capitalization, Gujarat Kidney & Super Speciality Ltd or Krishna Institute of Medical Sciences Ltd?

Market cap of Gujarat Kidney & Super Speciality Ltd is 1,289 Cr while Market cap of Krishna Institute of Medical Sciences Ltd is 29,480 Cr

What are the key factors driving the stock performance of Gujarat Kidney & Super Speciality Ltd and Krishna Institute of Medical Sciences Ltd?

The stock performance of Gujarat Kidney & Super Speciality Ltd and Krishna Institute of Medical Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Kidney & Super Speciality Ltd and Krishna Institute of Medical Sciences Ltd?

As of October 31, 2026, the Gujarat Kidney & Super Speciality Ltd stock price is INR ₹163.5. On the other hand, Krishna Institute of Medical Sciences Ltd stock price is INR ₹701.9.

How do dividend payouts of Gujarat Kidney & Super Speciality Ltd and Krishna Institute of Medical Sciences Ltd compare?

To compare the dividend payouts of Gujarat Kidney & Super Speciality Ltd and Krishna Institute of Medical Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.